The First Universal Opioid Ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): Characterization of the In Vitro Profile and In Vivo Behavioral Effects in Mouse Models of Acute Pain and Cocaine-Induced Reward

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2011-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.110.175620PMID 21177476PMCID PMC3061529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nociceptin/Orphanin FQ Receptor Activation Attenuates Antinociception Induced by Mixed Nociceptin/Orphanin FQ/μ-Opioid Receptor Agonists

  2009cited by this paper
• Comparison of the Antinociceptive and Antirewarding Profiles of Novel Bifunctional Nociceptin Receptor/μ-Opioid Receptor Ligands: Implications for Therapeutic Applications

  2009cited by this paper
• Activities of mixed NOP and μ‐opioid receptor ligands

  2008cited by this paper
• Effects of chronic buprenorphine treatment on levels of nucleus accumbens glutamate and on the expression of cocaine-induced behavioral sensitization in rats

  2008cited by this paper
• The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine.

  2008cited by this paper
• The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference.

  2007cited by this paper
• SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/μ-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice

  2007cited by this paper
• Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

  2007influential reference
• The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration

  2006cited by this paper
• Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP

  2005cited by this paper
• Rats Maintained Chronically on Buprenorphine Show Reduced Heroin and Cocaine Seeking in Tests of Extinction and Drug-Induced Reinstatement

  2005cited by this paper
• Randomized Trial of Buprenorphine for Treatment of Concurrent Opiate and Cocaine Dependence

  2004cited by this paper
• Buprenorphine: a unique drug with complex pharmacology.

  2004cited by this paper
• Buprenorphine

  2004cited by this paper
• Buprenorphine Antinociception is Abolished, but Naloxone-Sensitive Reward is Retained, in μ-Opioid Receptor Knockout Mice

  2004influential reference
• Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice

  2004cited by this paper
• Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors

  2003cited by this paper
• Acquisition, Expression, and Reinstatement of Ethanol-Induced Conditioned Place Preference in Mice: Effects of Opioid Receptor-Like 1 Receptor Agonists and Naloxone

  2003cited by this paper
• Formic Acid Catalyzed Rearrangement of Thevinols (=4,5‐Epoxy‐3,6‐dimethoxy‐α,17‐dimethyl‐6,14‐ethenomorphinan‐7‐methanols) and Their Vinylogous Analogues: Effects of 5β‐Methyl Substitution

  2003cited by this paper
• The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats.

  2003cited by this paper
• Orphanin FQ/nociceptin blocks methamphetamine place preference in rats

  2003cited by this paper
• Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference

  2002influential reference
• Orphanin FQ/nociceptin attenuates the development of morphine tolerance in rats

  2001cited by this paper
• HS‐599: a novel long acting opioid analgesic does not induce place‐preference in rats

  2001cited by this paper
• Effect of nociceptin on alcohol intake in alcohol-preferring rats

  1999cited by this paper
• Orphanin FQ/nociceptin blocks acquisition of morphine place preference.

  1999influential reference
• [Opioid receptor knockout mice].

  1999cited by this paper
• Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

  1998cited by this paper
• Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.

  1997cited by this paper
• Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor

  1995cited by this paper
• Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor

  1995cited by this paper
• Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

  1995cited by this paper
• Dissociation of buprenorphine-induced locomotor sensitization and conditioned place preference in rats.

  1994influential reference
• Naltrexone–Buprenorphine Interactions: Effects on Cocaine Self-Administration

  1993cited by this paper
• Cocaine conditioned place preference is attenuated by chronic buprenorphine treatment.

  1991cited by this paper
• Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse.

  1990cited by this paper
• Buprenorphine suppresses cocaine self-administration in rhesus monkeys.

  1989cited by this paper
• Buprenorphine.

  1985cited by this paper
• Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

  1978cited by this paper
• AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT

  1977influential reference
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• Novel analgesics and molecular rearrangements in the morphine-thebaine group. XXII. Deamination of 7 beta-aminomethyl-6,14-endo-etheno-7 alpha-methyl-6,7,8,14-tetrahydrothebaine.

  1971cited by this paper
• Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine.

  1967cited by this paper

• Opioid receptors in GtoPdb v.2025.3

  2025cites this paper
• Opioid receptors in GtoPdb v.2025.1

  2025cites this paper
• The Therapeutic Potential of Dual NMR (NOP/MOP) Agonism in Pain Management

  2025cites this paper
• Effects of the μ-opioid peptide and nociceptin/orphanin FQ peptide receptor agonist BU08028 on cocaine self-administration in male rhesus monkeys.

  2025cites this paper
• Effect of chronic delivery of the NOP/MOR partial agonist AT-201 and NOP antagonist J-113397 on heroin relapse in a rat model of opioid maintenance

  2024cites this paper
• Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy.

  2024cites this paper
• Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics

  2023cites this paper
• Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy

  2023cites this paper
• Opioid receptors in GtoPdb v.2023.1 Opioid receptors in GtoPdb v.2023.1

  2023cites this paper
• Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation

  2022cites this paper
• Interactions between opioids and stimulants: Behavioral pharmacology of abuse-related effects.

  2022cites this paper
• Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain

  2022cites this paper
• Potential therapeutic targets for the treatment of opioid abuse and pain.

  2022cites this paper
• Diels–Alder Adducts of Morphinan-6,8-Dienes and Their Transformations

  2022cites this paper
• Functional Profile of Systemic and Intrathecal Cebranopadol in Nonhuman Primates

  2021cites this paper
• The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies

  2021cites this paper
• The Role of Nociceptin in Opioid Regulation of Brain Functions

  2021cites this paper
• Profiling the Effects of Repetitive Morphine Administration on Motor Behavior in Rats

  2021cites this paper
• Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

  2021cites this paper
• Pharmacological Diversity in Opioid Analgesics: Lessons From Clinically Useful Drugs

  2021cites this paper
• Research progress on the potential novel analgesic BU08028.

  2021cites this paper
• Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists

  2021cites this paper
• Morphine alkaloids: History, biology, and synthesis.

  2021cites this paper
• Involvement of the nociceptin opioid peptide receptor in morphine-induced antinociception, tolerance and physical dependence in female mice

  2021cites this paper
• Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance

  2021cites this paper
• Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse

  2020cites this paper
• Nociceptin/orphanin FQ peptide receptor-related ligands as novel analgesics.

  2020cites this paper
• BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.

  2020cites this paper
• NOP-Related Mechanisms in Substance Use Disorders.

  2019cites this paper
• NOP-Targeted Nonpeptide Ligands.

  2019cites this paper
• NOP-Related Mechanisms in Pain and Analgesia.

  2019cites this paper
• Opioid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.

  2019cites this paper
• Bifunctional opioid receptor ligands as novel analgesics.

  2019cites this paper
• Current strategies toward safer mu opioid receptor drugs for pain management

  2019cites this paper
• Effects of NOP-Related Ligands in Nonhuman Primates.

  2019cites this paper
• Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.

  2019cites this paper
• Emerging Insights into Mu Opioid Pharmacology.

  2019cites this paper
• Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys

  2019cites this paper
• Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic

  2018cites this paper
• Progress in understanding mechanisms of opioid‐induced gastrointestinal adverse effects and respiratory depression

  2018cites this paper
• Age‐dependent antinociception and behavioral inhibition by morphine

  2018cites this paper
• Multifunctional Opioid Ligands.

  2018cites this paper
• Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile

  2018cites this paper
• A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates

  2018cites this paper
• Targeting multiple opioid receptors – improved analgesics with reduced side effects?

  2018influential citation
• Morphine dosing strategy plays a key role in the generation and duration of the produced antinociceptive tolerance.

  2017cites this paper
• Designing Safer Analgesics via μ-Opioid Receptor Pathways.

  2017cites this paper
• Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors

  2017cites this paper
• Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats

  2017cites this paper
• Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research

  2016cites this paper
• Central N/OFQ-NOP Receptor System in Pain Modulation.

  2016cites this paper
• A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates

  2016cites this paper
• Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.

  2016cites this paper
• Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management.

  2016cites this paper
• Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo)

  2016cites this paper
• C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors

  2015cites this paper
• BU08073 a buprenorphine analogue with partial agonist activity at μ‐receptors in vitro but long‐lasting opioid antagonist activity in vivo in mice

  2015cites this paper
• Multiple Mechanisms Underlying the Long Duration of Action of Thienorphine, A Novel Partial Opioid Agonist for the Treatment of Addiction

  2014cites this paper
• BU 08073 a Buprenorphine Analog with Partial Agonist Activity at mu Receptors in vitro but Long-Lasting Opioid Antagonist Activity in vivo in Mice 1

  2014cites this paper
• Opus: University of Bath Online Publication Store Open Peer Review

  2014cites this paper
• The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

  2013cites this paper
• Buprenorphine and related orvinols

  2013cites this paper
• Pharmacology of mixed NOP/mu ligands

  2013cites this paper
• Effects of Spinally Administered Bifunctional Nociceptin/Orphanin FQ Peptide Receptor/μ-Opioid Receptor Ligands in Mouse Models of Neuropathic and Inflammatory Pain

  2013cites this paper
• Pharmacological Investigation of NOP-Related Ligands as Analgesics without Abuse Liability

  2013cites this paper
• Structure-Activity Relationships of Nociceptin Receptor (NOP) Ligands and the Design of Bifunctional NOP/Mu Opioid Receptor-Targeted Ligands

  2013cites this paper
• Roles of Mu Opioid Receptors and Nociceptin/Orphanin FQ Peptide Receptors in Buprenorphine-Induced Physiological Responses in Primates

  2012influential citation
• [Dmt1]N/OFQ(1–13)‐NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist

  2012cites this paper
• Endogenous opiates and behavior: 2011.

  2012cites this paper
• The Posterior Ventral Tegmental Area Mediates Alcohol-Seeking Behavior in Alcohol-Preferring Rats

  2011cites this paper
• Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

  2011cites this paper
• Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

  2011cites this paper
• Targeting opioid and neurokinin-1 receptors to treat alcoholism.

  2011cites this paper
• Opus: University of Bath Online Publication Store Bu08073 a Buprenorphine Analog with Partial Agonist Activity at Mu Receptors in Vitro but Long- Lasting Opioid Antagonist Activity in Vivo in Mice

  year unknowncites this paper